gemtuzumab ozogamicin + nucleoside antagonist

Gemtuzumab ozogamicin + nucleoside antagonist refers to a combination chemotherapy regimen primarily used in the treatment of CD33-positive acute myeloid leukemia (AML). Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) consisting of a humanized anti-CD33 monoclonal antibody linked to a cytotoxic calicheamicin derivative. Upon binding to CD33 on leukemic blasts, the ADC is internalized, and the calicheamicin payload is released, causing double-strand DNA breaks and cell death. Nucleoside antagonists, such as cytarabine (Ara-C), are antimetabolites that inhibit DNA synthesis by competing with natural nucleosides for incorporation into DNA or by inhibiting DNA polymerase. The combination of these agents provides a synergistic effect by targeting leukemic cells through both targeted delivery of a potent toxin and broad inhibition of DNA replication. This regimen, often administered with an anthracycline (e.g., daunorubicin), has demonstrated improved event-free survival in patients with de novo AML.

Brand names

Mylotarg

Other names

gemtuzumab ozogamicin + cytarabinegemtuzumab ozogamicin + Ara-Cgemtuzumab ozogamicin + fludarabinegemtuzumab ozogamicin + cladribine